Preliminary pharmacokinetics of PEGylated oxaliplatin polylactic acid nanoparticles in rabbits and tumor-bearing mice

Artificial Cells, Nanomedicine and Biotechnology

Volumn 43, Issue 4, 2015, Pages 258-262

  Wei, Haitian ^a   Xu, Lisa ^a   Sun, Yong ^a   Li, Gaohong ^b   Cui, Zhaoyuan ^a   Yan, Guowen ^a   Chen, Qian ^a   Yin, Hongli ^a   Ma, Chao ^a  

^a Department of Pharmaceutical ^*  (China)

^b Qingdao Central Hospital   (China)

Author keywords

Nanoparticle; Oxaliplatin; Pharmacokinetics; Tumor

Indexed keywords

MAMMALS; NANOPARTICLES; PARTICLE SIZE; PHARMACOKINETICS; POLYESTERS;

CLINICAL APPLICATION; COLLOIDAL SOLUTIONS; DRUG CONCENTRATION; NANOPARTICLE (NPS); OXALIPLATIN; POLY LACTIC ACID; RABBIT PLASMAS; TISSUE DISTRIBUTIONS;

TUMORS;

MACROGOL 4000; NANOPARTICLE; OXALIPLATIN; POLYLACTIC ACID; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; PLATINUM COMPLEX; POLYETHYLENE GLYCOL 1000; POLYMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL COUNTING CHAMBER; COLLOID; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; HEART; KIDNEY; MOUSE; NEOPLASM; NEW ZEALAND RABBIT; NONHUMAN; PARTICLE SIZE; ANIMAL; CHEMISTRY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; RABBIT;

ANIMALS; DRUG CARRIERS; LACTIC ACID; MICE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; POLYMERS; RABBITS;

EID: 84953864978     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.883402     Document Type: Article

References (10)

1. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649-1659.
2. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631-651.
3. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331-332.
4. Cui Z, Sun Y, Liu X, Ju F, Chen Q, Gao W, Wei H. 2013. Preparation and evaluations in vitro of Oxaliplatin polylactic acid nanoparticles. Artif Cells Nanomed Biotechnol. 41:227-231.
5. Feng SS, Huang GF. 2001. Efects of emulsifers on the controlled release of paclitaxel (Taxo1) from nanospheres of biodegradable polymers. J Control Release 71:53-69.
6. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. 2000. Stealth corona-core nanoparticles surface modi-fied by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 18:301-313.
7. Kim K, Yu M, Zong X, Chiu J, Fang D, Seo YS, et al. 2003. Control of degradation rate and hydrophilicity in electrospun non-woven poly (D, L-lactide) nanofber scafolds for biomedical applications. Bio-materials 24:4977-4985.
8. ® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121-128.
9. Schadlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Göpferich A, et al. 2011. Tumor accumulation of NIR fuorescent PEG-PLA nanoparticles: Impact of particle size and human xenograft tumor model. ACS Nano 5:8710-8720.
10. Vauthier C, Cabane B, Labarre D. 2008. How to concentrate nanopar-ticles and avoid aggregation. Eur J Pharm Biopharm 69:466-475.